Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.

Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.

Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.

Background reading: 

• How Ozempic’s maker lost its shine after creating a wonder drug.
• What Trump’s new drug pricing deal means for people with obesity.

Photo: Sergei Gapon/Agence France-Presse — Getty Images

For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.